This inventor holds 1 USPTO granted patent. Top assignee: Medifron Dbt Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Jae Hong Im: Innovator in O-GlcNAcase Inhibition
Introduction
Jae Hong Im is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of biochemistry, particularly in the development of compounds that target specific enzymatic activities. His work is crucial for advancing therapeutic options in various medical conditions.
Latest Patents
Jae Hong Im holds a patent for a compound having inhibitory activity against O-GlcNAcase. This invention relates to a novel compound that demonstrates the ability to inhibit the activity of O-GlcNAcase, which is significant for potential therapeutic applications. The patent highlights the compound's unique properties and its potential uses in medical treatments.
Career Highlights
Currently, Jae Hong Im is associated with Medifron Dbt Inc., where he continues to engage in innovative research and development. His work at the company focuses on creating solutions that address critical health challenges through biochemical advancements.
Collaborations
Jae Hong Im collaborates with talented colleagues, including Hee Kim and Hee Jin Ha. Together, they contribute to the research and development efforts at Medifron Dbt Inc., fostering an environment of innovation and teamwork.
Conclusion
Jae Hong Im's contributions to the field of biochemistry, particularly through his patent on O-GlcNAcase inhibition, showcase his dedication to advancing medical science. His work at Medifron Dbt Inc. and collaborations with fellow researchers further emphasize his role as a key innovator in the industry.